BBS10

Across TCGA pan-cancer cohorts, BBS10 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated BBS10 data layer compared with 26 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher BBS10 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated BBS10 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, LIHC, and CESC are the cancer types where BBS10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.209	0.729	<.001	47	view →
LIHC	OS	Median	All	0.145	0.779	<.001	39	view →
CESC	OS	Median	III,IV	0.091	0.755	<.001	24	view →
SKCM	OS	Median	All	0.353	0.784	.011	12	view →
UCEC	DFS	Median	II,III,IV	0.922	0.436	.022	6	view →
LUSC	DFS	Median	All	0.136	0.791	.005	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

BBS10–HNSC (OS)

Open the HNSC breakdown →